Randomized Controlled Trial (RCT)

Key facts

Control types (21 CFR 314.126)

Placebo, dose comparison, no treatment, active treatment, historical

Evidence standard

Adequate and well-controlled investigations, FD&C Act Section 505(d)

Masking options

Open-label, single-blind or double-blind

What is a randomized controlled trial?

In an RCT, a random process, not the investigator or the participant, decides who gets the new treatment and who gets the comparison. With enough participants, randomization balances known and unknown factors, such as age, disease severity and lifestyle, across groups. That balance is what allows causal conclusions.

The control group may receive a placebo, an existing standard treatment, a different dose or no treatment. RCTs are the usual design for Phase 3 trials and are widely regarded as the strongest single-study design for measuring whether a treatment works.

How RCTs are designed

Key design choices include:

• Allocation: simple, block or stratified randomization, often managed by an interactive response system.
• Masking: open-label, single-blind or double-blind, to keep expectations from biasing results.
• Structure: parallel groups, crossover designs in which each participant receives both treatments in sequence, or factorial designs.
• Hypothesis: superiority, showing the treatment is better than control, or noninferiority, showing it is not unacceptably worse.
• Analysis: intention-to-treat analysis keeps participants in their assigned group regardless of what happened later.

Why RCTs matter

FDA approval generally requires substantial evidence from adequate and well-controlled investigations, and FDA regulations at 21 CFR 314.126 list the kinds of control that qualify. Payers and health technology assessment bodies also weigh RCT evidence heavily in coverage decisions.

For market analysts, the comparator matters as much as the result. A win against placebo supports approval, while a head-to-head win against a competitor supports pricing and formulary position.

RCTs vs real-world studies

RCTs have strong internal validity but often enroll narrow populations under tightly controlled conditions, so results may not match routine practice. Real-world evidence from claims, electronic health records and registries complements RCTs, and pragmatic trials randomize patients within usual care to capture some strengths of both.